Grinevich V, Fournier A, Pelletier G
MRC Group in Molecular Endocrinology, CHUL Research Center and Laval University, Québec, Canada.
Brain Res. 1997 Oct 31;773(1-2):190-6. doi: 10.1016/s0006-8993(97)01011-1.
Pituitary adenylate cyclase-activating peptide (PACAP) is a 38-amino-acid polypeptide, first isolated from hypothalamus, which directly stimulates in vitro the production of cAMP as well as the release of several pituitary hormones, such as growth hormone and luteinizing hormone. In vivo, PACAP has been shown to stimulate ACTH release. The presence of PACAP receptors in several brain areas, including the hypothalamus, suggests that this peptide might play a role as a neurotransmitter/neuromodulator and might be involved in the regulation of hypophysiotropic neurohormones. In order to study the role of PACAP on corticotropin-releasing hormone (CRH) neuron, we have investigated the effects of intracerebroventricular (i.c.v.) and intravenous (i.v.) injections of PACAP and the potent PACAP antagonist PACAP(6-38) on CRH gene expression in the hypothalamic paraventricular nucleus (PVN) in the male rat. The levels of CRH mRNA were evaluated by quantitative in situ hybridization. The i.c.v. injection of PACAP (4 microg/kg b.wt.) produced a 22% increase in the hybridization signal, an effect which was completely prevented by the concomitant injection of the PACAP antagonist (4 microg/kg b.wt.). On the other hand, the administration of the PACAP antagonist induced by itself a 40% decrease in the amounts of CRH mRNA. The i.v. injection of the same peptides (100 microg/kg. b.wt.) produced very similar results. These data strongly suggest that PACAP is involved in the positive regulation of CRH gene expression via specific central receptors and then can play a role as a neurotransmitter/neuromodulator. The effect observed after i.v. injection of PACAP also suggests that the circulating levels of PACAP can play a role in the modulation of CRH gene expression. PACAP might then be involved in the regulation of the HPA axis by a double mechanism: stimulation of CRH gene expression at the central level and direct effect on pituitary corticotrophs.
垂体腺苷酸环化酶激活肽(PACAP)是一种由38个氨基酸组成的多肽,最初从下丘脑分离得到,它能在体外直接刺激环磷酸腺苷(cAMP)的产生以及多种垂体激素的释放,如生长激素和促黄体生成素。在体内,PACAP已被证明能刺激促肾上腺皮质激素(ACTH)的释放。PACAP受体存在于包括下丘脑在内的多个脑区,这表明该肽可能作为神经递质/神经调节剂发挥作用,并可能参与促垂体神经激素的调节。为了研究PACAP对促肾上腺皮质激素释放激素(CRH)神经元的作用,我们研究了脑室注射(i.c.v.)和静脉注射(i.v.)PACAP以及强效PACAP拮抗剂PACAP(6 - 38)对雄性大鼠下丘脑室旁核(PVN)中CRH基因表达的影响。通过定量原位杂交评估CRH mRNA的水平。脑室注射PACAP(4微克/千克体重)使杂交信号增加了22%,而同时注射PACAP拮抗剂(4微克/千克体重)则完全阻断了这一效应。另一方面,单独注射PACAP拮抗剂可使CRH mRNA的量减少40%。静脉注射相同剂量的肽(100微克/千克体重)产生了非常相似的结果。这些数据强烈表明,PACAP通过特定的中枢受体参与CRH基因表达的正向调节,进而可作为神经递质/神经调节剂发挥作用。静脉注射PACAP后观察到的效应还表明,PACAP的循环水平可参与CRH基因表达的调节。PACAP可能通过双重机制参与下丘脑 - 垂体 - 肾上腺(HPA)轴的调节:在中枢水平刺激CRH基因表达以及对垂体促肾上腺皮质细胞产生直接作用。